These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Sorsby's fundus dystrophy tissue inhibitor of metalloproteinases-3 (TIMP-3) mutants have unimpaired matrix metalloproteinase inhibitory activities, but affect cell adhesion to the extracellular matrix. Yeow KM; Kishnani NS; Hutton M; Hawkes SP; Murphy G; Edwards DR Matrix Biol; 2002 Jan; 21(1):75-88. PubMed ID: 11827795 [TBL] [Abstract][Full Text] [Related]
9. Localization of TIMP-3 mRNA expression to the retinal pigment epithelium. Della NG; Campochiaro PA; Zack DJ Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1921-4. PubMed ID: 8759363 [TBL] [Abstract][Full Text] [Related]
10. Adenovirus mediated gene delivery of tissue inhibitor of metalloproteinases-3 induces death in retinal pigment epithelial cells. Majid MA; Smith VA; Easty DL; Baker AH; Newby AC Br J Ophthalmol; 2002 Jan; 86(1):97-101. PubMed ID: 11801512 [TBL] [Abstract][Full Text] [Related]
11. Analysis of the collagen VI assemblies associated with Sorsby's fundus dystrophy. Knupp C; Chong NH; Munro PM; Luthert PJ; Squire JM J Struct Biol; 2002; 137(1-2):31-40. PubMed ID: 12064931 [TBL] [Abstract][Full Text] [Related]
12. Matrix bound SFD mutant TIMP-3 is more stable than wild type TIMP-3. Majid MA; Smith VA; Newby AC; Dick AD Br J Ophthalmol; 2007 Aug; 91(8):1073-6. PubMed ID: 17383996 [TBL] [Abstract][Full Text] [Related]
13. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Weber BH; Vogt G; Pruett RC; Stöhr H; Felbor U Nat Genet; 1994 Dec; 8(4):352-6. PubMed ID: 7894485 [TBL] [Abstract][Full Text] [Related]
14. A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby's fundus dystrophy. Langton KP; McKie N; Curtis A; Goodship JA; Bond PM; Barker MD; Clarke M J Biol Chem; 2000 Sep; 275(35):27027-31. PubMed ID: 10854443 [TBL] [Abstract][Full Text] [Related]
15. A mouse model for Sorsby fundus dystrophy. Weber BH; Lin B; White K; Kohler K; Soboleva G; Herterich S; Seeliger MW; Jaissle GB; Grimm C; Reme C; Wenzel A; Asan E; Schrewe H Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2732-40. PubMed ID: 12147610 [TBL] [Abstract][Full Text] [Related]
16. TIMP-3 mRNA is not overexpressed in Sorsby fundus dystrophy. Chong NH; Kvanta A; Seregard S; Bird AC; Luthert PJ; Steen B Am J Ophthalmol; 2003 Nov; 136(5):954-5. PubMed ID: 14597066 [TBL] [Abstract][Full Text] [Related]
17. Sorsby fundus dystrophy - A review of pathology and disease mechanisms. Christensen DRG; Brown FE; Cree AJ; Ratnayaka JA; Lotery AJ Exp Eye Res; 2017 Dec; 165():35-46. PubMed ID: 28847738 [TBL] [Abstract][Full Text] [Related]
18. Sorsby fundus dystrophy mutation Timp3(S156C) affects the morphological and biochemical phenotype but not metalloproteinase homeostasis. Soboleva G; Geis B; Schrewe H; Weber BH J Cell Physiol; 2003 Oct; 197(1):149-56. PubMed ID: 12942551 [TBL] [Abstract][Full Text] [Related]
19. [Antiangiogenic therapy in Sorsby's fundus dystrophy without a mutation in the TIMP-3 gene]. Copete-Piqueras S; Cava-Valenciano C; Flores-Moreno I; Moreno-Valladares A; Bautista Ruescas V Arch Soc Esp Oftalmol; 2013 Jun; 88(6):240-3. PubMed ID: 23726310 [TBL] [Abstract][Full Text] [Related]
20. A novel His158Arg mutation in TIMP3 causes a late-onset form of Sorsby fundus dystrophy. Lin RJ; Blumenkranz MS; Binkley J; Wu K; Vollrath D Am J Ophthalmol; 2006 Nov; 142(5):839-48. PubMed ID: 16989765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]